LISAvienna e-Newsletter

Use this area to offer a short preview of your email's content.
View this email in your browser

Dear Readers,

Welcome to our new LISAvienna e-Newsletter providing you with the hottest news on the Life Science City Vienna every two month.

Review: BIO-Europe 2013 in Vienna
BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. Over 3,200 delegates from 1,841 companies representing 56 countries attended this year. There were 184 company presentations with close to 3,600 licensing opportunities on offer and 95 exhibits.

Next LISAvienna Business Seminar
January 16, 2014: The aspects of the technical documentation for instruction manuals of medical devices. For registration please click here.

New service: Bulletin Board
Please check out our website for our new service: with the LISAvienna bulletin board you can easily find seminars, job opportunities and laboratory spaces in Vienna!

We hope you enjoy the LISAvienna e-Newsletter!

Season's Greetings,
LISAvienna

NEWSFLASH - hottest news on the Life Science City Vienna

APEPTICO publishes significant scientific results of its development compound AP301

3.12.2013 - APEPTICO today announced that significant scientific results of its development compound AP301 have been published in Molecular Pharmacology and The Journal of Clinical Pharmacology, summarising the mode of action of AP301 in activating the amiloride-sensitive epithelial sodium ion channel (ENaC) and presenting the results of APEPTICOâ€™s first-in-man clinical study of orally inhaled AP301. Â» read more

Vetmeduni Vienna: Researchers find protein that regulates the burning of body fat

19.11.2013 - Muscle movements generate body heat. However, body heat can also be generated in another way: body fat contains a small number of brown adipose cells â€“ special fat cells that can generate heat without muscle activity. Â» read more

EBD Group: BIO-EuropeÂ® 2013 breaks all previous records for attendance and partnering

14.11.2013 - The 19th annual BIO-EuropeÂ® international partnering conference (November 4â€“6) wrapped up last week in Vienna, Austria. The conference, organized by EBD Group in collaboration with the Biotechnology Industry Organization (BIO) and local host Life Science Austria Vienna (LISAvienna), featured nearly 18,000 one-to-one partnering meetings, an all-time record. Â» read more

For pictures of the conference please click here.

MedUni Vienna: 7-Tesla MRI scanner supports research into multiple sclerosis

11.11.2013 - Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system, the cause of which is still not yet fully understood. MS is also known as the â€œdisease with many faces.â€ The progression of the disease is hard to predict in each individual. Â» read more

Miracor successfully completes enrollment of 30 patients in a safety and feasibility study using its PICSOÂ® system to treat severe heart attack patients post-primary PCI

11.11.2013 - Miracor Medical Systems GmbH announced today that 30 patients have been successfully treated with no device-related adverse events using its PICSOÂ®. Â» read more

Themis Bioscience: "New" Infectious Diseases - Clinical tests on innovative
Themis vaccine

7.11.2013 - A vaccine against the dreaded Chikungunya fever, developed by Vienna-based biotech company Themis Bioscience, is now undergoing clinical testing for the first time. Â» read more

Hookipa Biotech closes â‚¬20 Million
($27.5 Million) in Series B Financing

4.11.2013 - Funds to be used to progress viral vaccine pipeline and to explore applications in cancer immunotherapy. Â» read more

S-TARget Achieves Clinical Proof of Concept for Allergy Vaccine SG100 in Asthmatic Non-human Primates

10.10.2013 - S-TARget therapeutics (â€œS-TARgetâ€), a biotechnology company developing vaccines that address the cause of severe allergic diseases, announced today that it has achieved clinical proof of concept ... Â» read more

Arsanis Inc Closes $20 Million Series B Financing

3.9.2013 - Arsanis Inc, a privately-held biotechnology company developing human monoclonal antibodies for severe infectious diseases, today announced that it has raised $20 million in a Series B financing. Â» read more

This list is not exhaustive. For more news please visit our website www.LISAvienna.at.

Upcoming EVENTS in Vienna

WKO Branchenfokus Medizintechnik USA
February 5 - 6, 2014 - Wirtschaftskammer Ã–sterreich, Wiedner HauptstraÃŸe 63, 1045 Vienna
Info & Registration

ECR (European Congress of Radiology)
March 6 - 10, 2014 - Austria Center Vienna, Bruno-Kreisky-Platz 1, 1220 Vienna
Info & Registration

DIA EuroMeeting Vienna
March 25 - 27, 2014 - Austria Center Vienna, Bruno-Kreisky-Platz 1, 1220 Vienna
Info & Registration

This list is not exhaustive. For more events please visit our website www.LISAvienna.at.